The Tim Ferriss Show Transcripts: The Random Show — The 2–2–2 Rule, The Future of AI, Bioelectric Medicine, Surviving Modern Dating, The Promises of DORAs for Alzheimer’s, and Wisdom from Anthony de Mello ( #838)
Please enjoy this transcript of another wide-ranging “Random Show” episode that I recorded with my close friend Kevin Rose (digg.com)! We explore the promises of DORAs for Alzheimer’s, Kevin’s AI stack and where AI is heading, the challenges of modern dating, wisdom from Anthony de Mello, bioelectric medicine, and much, much more. Transcripts may contain a few […]
Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment – Reuters
Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment Reuters
Jim Cramer on Pfizer: “I Would Hold on to It”
Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer was recently asked about. During the episode, a caller inquired if the company has any growth potential or if PFE is a dividend play. In response, Cramer said: “2026, yeah, there is. It’s got, they got a lot of irons in the fire. I think […]
When Is the Best Time to Eat Protein?
Proteins work around the clock to keep your body running. These vital molecules handle the building and repair of your tissues, from your muscles to your organs. They also play an essential role in keeping your enzymes, hormones, and immune system functioning as they should. They’re made up of smaller components called amino acids, and […]
Details of failed studies cast pall on Novo Nordisk’s GLP-1 as Alzheimer’s treatment
The joint studies showed some improvement in a few biological measures of the disease, but most of the changes were small and not enough to make a difference in delaying cognitive decline.
Diabetes drugs linked to slower frailty progression in older adults
A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic) and liraglutide (Victoza)-experience slower progression of frailty over one year compared with those starting other diabetes medications.
失败研究的细节为诺和诺德GLP-1作为阿尔茨海默病治疗方案蒙上阴影
Details of failed studies cast pall on Novo Nordisk”s GLP-1 as Alzheimer”s treatment (www.reuters.com) 09:06
The Random Show — The 2–2–2 Rule, The Future of AI, Bioelectric Medicine, Surviving Modern Dating, The Promises of DORAs for Alzheimer’s, and Wisdom from Anthony de Mello ( #838)
Welcome to another wide-ranging “Random Show” episode that I recorded with my close friend Kevin Rose (digg.com)! We explore the promises of DORAs for Alzheimer’s, Kevin’s AI stack and where AI is heading, the challenges of modern dating, wisdom from Anthony de Mello, bioelectric medicine, and much, much more. Please enjoy! This episode is brought to you […]
Lilly (NYSE: $LLY) Jumps as FDA Expands Jaypirca Use
Lilly (NYSE: $LLY) Jumps as FDA Expands Jaypirca Use Eli Lilly and Company BATS:LLY DEXWireNews Eli Lilly and Company (NYSE: LLY ) received a major regulatory boost after the U.S. Food and Drug Administration approved an expanded indication for its non-covalent BTK inhibitor, Jaypirca (pirtobrutinib). The drug is now approved for adults with relapsed or […]
Ozempic Improves Glycemic Control, Cuts Weight in Schizophrenia Patients
(MedPage Today) — Low-dose semaglutide (Ozempic, Wegovy) improved glycemic control and weight outcomes in a randomized trial of adults whose schizophrenia was being treated with the second-generation antipsychotics clozapine or olanzapine.
The…